Eric Schneiderman defended a controversial lawsuit against the British bank Barclays and opposed its motion to dismiss the case.» Read More
The Fed's move to end its asset purchasing program will cause a "collapse in asset prices and a severe recession," according to Michael Pento.
There are so many big names at Milken's annual Global Conference in Los Angeles that billionaires don't automatically get VIP treatment.
Commodities trader Dennis Gartman explains why he's getting out of stocks.
Argus Research's John Eade weighs in on growing M&A in the pharma space.
Though it may feel like high-frequency trading is taking over the world, volume actually has been pretty flat in 2014.
American Realty is in talks to buy NorthStar Realty, according to sources, in a deal that would combine a major property owner with a real estate financing company.
Bank of America revised its previously announced regulatory capital ratios downward, the company announced Monday.
Computer algorithms are deciding on a daily basis which way stocks go and that's holding investors hostage, small-cap stock picker Craig Hodges tells CNBC.
Private equity firm KKR plans to allow investors to sell parts of their stake in buyout funds through a new private market run by Nasdaq.
For years, Wall Street pros have been bemoaning the exodus of mom-and-pop investors. Recent data suggest the trend might be changing.
Maybe it was the martini that helped Carl Icahn publicly support longtime nemesis Bill Ackman, but he still calls Marty Lipton "dead wrong."
A new survey shows that many on Wall Street agree with Michael Lewis that U.S. equity markets aren't fair.
Citigroup now needs a steady hand to bring the bank to its full potential, Dick Bove says.
The new Fed chair faces the challenge to either resist or go along with conventional wisdom to hold the line on interest rates.
Expectations are building that the ECB may consider QE to stimulate the economy, but some say it might not be the panacea investors are hoping for.
One astute trader picked up big money overnight by buying options in Furiex Pharmaceuticals.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
When asked how much he'd like to invest in seeding new activist funds, Icahn said investing $1 billion would be extremely immaterial to his firm.
Hedge fund manager Bill Ackman promised to pay a disgruntled ex-Herbalife executive as much as $3.60 million over the next 10 years, a report said.
Greenlight Capital supports IEX and holds a stake in it.
Get the best of CNBC in your inbox